India, Jan. 29 -- OS Therapies, Inc. (OSTX) Wednesday announced that it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related intellectual property from Ayala Pharmaceuticals (ADXS).
Under the agreement, OS Therapies will pay $0.5 million in cash and issue $7.5 million in common shares to Ayala.
This acquisition includes a Phase 2 lung cancer and Phase 1 prostate cancer program, as well as full ownership of the IP related to OS Therapies' lead asset, OST-HER2, for osteosarcoma and other HER2-related indications.
The transaction is expected to close within 60 days from execution of the deal.
Meanwhile, OS Therapies anticipates requesting Biologics Licensing Authoriza...